HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Olanow, C. W. Search for Related Content PubMed PubMed Citation Articles by Olanow, C. W.

Can we achieve neuroprotection with currently available anti-parkinsonian interventions?

From the Department of Neurology, Mount Sinai School of Medicine, New York.

Address correspondence and reprint requests to C. Warren Olanow, MD, FRCPC, Department of Neurology, Mount Sinai School of Medicine, New York warren.olanow{at}mssm.edu

A disease-modifying therapy is the most important unmet medical need in the treatment of Parkinson disease (PD). Laboratory studies have identified many promising candidate agents, but none has been proven to be neuroprotective in PD. A major limitation has been the development of an endpoint that accurately reflects the underlying disease state. This dramatically limits the potential for a new drug being approved as a disease-modifying agent in PD. For the present, the best opportunity to provide patients with PD with a disease-modifying effect is with agents that have been approved for their symptomatic effects. This article reviews currently available drugs for PD and considers the evidence that they might have neuroprotective effects in PD.

Disclosure: C.W.O. has served as a consultant for Teva Neuroscience, Boehringer Ingleheim, Novartis, and Ceregene.